Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 93-98

  Seo, J S ^a   Cho, N Y ^b   Kim, H R ^c   Tsurumi, T ^d   Jang, Y S ^c   Lee, W K ^b   Lee, Suk Kyeong ^a  

^a The Catholic University of Korea   (South Korea)

^b Myong Ji University   (South Korea)

^c Chonbuk National University   (South Korea)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cell cycle; Epstein Barr virus; Epstein Barr virus lytic replication; Histone deacetylase inhibitor; Tricostatin A

Indexed keywords

CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 1C; HISTONE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P21; TRICHOSTATIN A;

ACETYLATION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL TRANSFORMATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DEACETYLATION; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOSURVEILLANCE; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; RIBONUCLEASE PROTECTION ASSAY; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 38749138063     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.93     Document Type: Article

References (38)

1. Van Lint C, Emiliani S and Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253, 1996.
2. Kuo MH and Allis CD: Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20: 615-626, 1998.
3. Gregory PD, Wagner K and Horz W: Histone acetylation and chromatin remodeling. Exp Cell Res 265: 195-202, 2001.
4. Struhl K: Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12: 599-606, 1998.
5. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM and Pestell RG: Histone acetylation and the cell-cycle in cancer. Front Biosci 6: D610-D629, 2001.
6. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
7. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
8. Konstantinopoulos PA and Papavassiliou AG: Chromatin-modulating agents as epigenetic anticancer drugs - 'the die is cast'. Drug Discov Today 11: 91-93, 2006.
9. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000.
10. Kim MS, Blake M, Baek JH, Kohlhagen G, Ponimier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003.
11. Klein G: Role of EBV and Ig/myc translocation in Burkitt lymphoma. Antibiot Chemother 46: 110-116, 1994.
12. Chapman AL and Rickinson AB: Epstein-Barr virus in Hodgkin's disease. Ann Oncol 9 (Suppl. 5): S5-S16, 1998.
13. Rickinson AB: Epstein-Barr virus. Virus Res 82: 109-113, 2002.
14. Friedrich RE, Bartel-Friedrich S, Lobeck H, Niedobitek G and Arps H: Epstein-Barr virus DNA and epithelial markers in nasopharyngeal carcinoma. Med Microbiol Immunol 192: 141-144, 2003.
15. Young LS and Murray PG: Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108-5121, 2003.
16. Takase K, Kelleher CA, Terada N, Jones JF, Lucas JJ and Gelfand EW: Dissociation of EBV genome replication and host cell proliferation in anti-IgG-stimulated Akata cells. Clin Immunol Immunopathol 81: 168-174, 1996.
17. Flemington E and Speck SH: Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol 64: 1217-1226, 1990.
18. Baumann M, Mischak H, Dammeier S, et al: Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation. J Virol 72: 8105-8114, 1998.
19. Gradoville L, Kwa D, El-Guindy A and Miller G: Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol 76: 5612-5626, 2002.
20. Countryman J, Jenson H, Seibl R, Wolf H and Miller G: Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 61: 3672-3679, 1987.
21. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W and Delecluse HJ: The Epstein-Ban virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19: 3080-3089, 2000.
22. Rickinson AB: Immune intervention against virus-associated human cancers. Ann Oncol 6 (Suppl. 1): 69-71, 1995.
23. Chapman AL, Rickinson AB, Thomas WA, Jarrett RE, Crocker J and Lee SP: Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res 61: 6219-6226, 2001.
24. + Hodgkin's disease. J Exp Med 200: 1623-1633, 2004.
25. Fogg MH, Garry D, Awad A, Wang F and Kaur A: The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques. J Immunol 176: 3391-3401, 2006.
26. Park JG, Lee JH, Kang MS, et al: Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 62: 276-282, 1995.
27. Lee WK, Kim SM, Sim YS, Cho SG, et al: B-Lympho-blastoid cell lines from cancer patients. In Vitro Cell Dev Biol 34: 97-101, 1998.
28. Daikoku T, Kudoh A, Fujita M, Sugaya Y, Isomura H, Shirata N and Tsurumi T: Architecture of replication compartment formed during Epstein-Ban virus lytic repliation. J Virol 79: 3409-3418, 2005.
29. Pokrovskaja K, Ehlin-Henriksson B, Bartkova J, et al: Pheno-type-related differences in the expression of D-type cyclins in human B cell-derived lines. Cell Growth Differ 7: 1723-1732, 1996.
30. Chen WJ, Chang CY and Lin JK: Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip). Biochem Pharmacol 65: 1777-1785, 2003.
31. Shin JY, Kim HS, Park J, Park JB and Lee JY: Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res 60: 262-265, 2000.
32. Samuelsson MK, Pazirandeh A and Okret S: A pro-apoptotic effect of the CDK inhibitor p57(Kip2) on staurosporine-induced apoptosis in HeLa cells. Biochem Biophys Res Commun 296: 702-709, 2002.
33. Feng WH, Cohen JI, Fischer S, et al: Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 96: 1691-1702, 2004.
34. Wang H and Cao Y: BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells. Anticancer Res 24: 67-74, 2004.
35. Countryman J and Miller G: Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci USA 82: 4085-4089, 1985.
36. Hardwick JM, Lieberman PM and Hayward SD: A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62: 2274-2284, 1988.
37. Ragoczy T, Heston L and Miller G: The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 72: 7978-7984, 1998.
38. Jenkins PJ, Binne UK and Fanell PJ: Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol 74: 710-720, 2000.